Bausch Health Companies Inc. (BHC) research

Bausch Health Companies Inc.
ShareXLinkedInReddit
Sector
Pharmaceuticals
Last price
$5.81
As of

Bausch Health Companies Inc. (BHC): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-07-30.

As of . Source: SEC EDGAR filings for BHC. Method and limitations.

SHARE THIS CARD

Share the BHC intelligence card

A branded snapshot of BHC: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion BHC intelligence card preview
Post to X
LIVE TERMINAL

See BHC live in the terminal

Track BHC's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live BHC terminal, free

Active signals for BHC

FREE, NO ACCOUNT

Every signal on BHC, as it fires

You are seeing 5 of 27 signals recorded on BHC since 2026-05-30.

The five above landed across 2 days. The other 22 were recorded on 3 other days. 18 of the 27 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in BHC (2026Q2)

Manager / securityMarket value% portfolioQoQ
D. E. Shaw & Co., Inc.CUSIP 071734107 · 2026Q2$13.3M0.01%,
Point72 Asset Management, L.P.CUSIP 071734107 · 2026Q2$11M0.01%,
TWO SIGMA INVESTMENTS, LPCUSIP 071734107 · 2026Q2$10.5M0.01%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 071734107 · 2026Q2$6.5M0.01%,
CITADEL ADVISORS LLCCUSIP 071734107 · 2026Q2$5.4M0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP 071734107 · 2026Q2$5.4M0.00%,
Bridgewater Associates, LPCUSIP 071734107 · 2026Q2$4.3M0.02%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, BHC

BHC against its peers

BHC's operating margin of 17.7% ranks in the 78th percentile of 19 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.

MetricBHCPeer medianPercentilen
Revenue FY10.3B USD451M USD9821
Gross marginn/a53.3%n/a7
Operating margin17.7%2.6%7819
Net margin1.5%-2.6%6020
Return on equityn/a-14.3%n/a22
P / E13.8x15.3x359

Peers (25): TRVI, NUVB, OCUL, NKTR, SUPN, HRMY, GPCR, ANIP, XERS, OMER, INVA, PAHC, OGN, AMLX, TARS, ANRO, ALMS, AMPH, PCRX, ESPR, ACRS, LQDA, AMRX, COLL, AXSM. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (BHC: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more BHC signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to BHCand get the insider, 13F, options, and confluence read in one view.

Open the live BHC terminal, free